Tag: Gilead Sciences

BioTech

Healthcare Active runners: Zogenix (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX), Galena Biopharma (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD)

Officials with Zogenix Inc. (NASDAQ:ZGNX), the San Diego-based maker of Zohydro, did not return a message seeking comment about the drug. The company is marketing the drug as the first extended-release hydrocodone pain reliever without acetaminophen, which can cause liver failure if taken in excess. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -14.18% in last session and finished the day at $3.84. Traded volume was 9.38million … Continue reading Healthcare Active runners: Zogenix (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX), Galena Biopharma (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD)

Kristen Barton
FB Nasdaq FB Facebook
Analyst Actions

Gilead (NASDAQ:GILD) Altripla Recall a Non-Issue According to Deutsche Bank

Deutsche Bank said Gilead(NASDAQ:GILD)’s Atripla recall is not an issue. The firm said Gilead proactively issued the recall following a typical quality check that found small particles and notes the company has multiple manufacturers for Atripla. Management said it was a minor issue and that Atripla supply is more than enough. Shares are Buy rated with a $132 price target. In a note issued by … Continue reading Gilead (NASDAQ:GILD) Altripla Recall a Non-Issue According to Deutsche Bank

John Meady
BioTech

Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Rexahn Pharmaceuticals (NYSEMKT:RNN), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -3.34% in last session and finished the day at $8.69. Traded volume was 1,200.00 shares in the last session and the average volume of the stock remained 26.48 million shares. The beta of the stock remained 1.64. Ariad Pharmaceuticals, Inc. … Continue reading Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Rexahn Pharmaceuticals (NYSEMKT:RNN), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Kevin Long
Finance

Nasdaq active movers: Facebook Inc (NASDAQ:FB), Sirius XM Holdings (NASDAQ:SIRI), QUALCOMM (NASDAQ:QCOM), Glu Mobile Inc. (NASDAQ:GLUU), Gilead Sciences, Inc. (NASDAQ:GILD)

Facebook Inc said the US Securities and Exchange Commission dropped its probe into the social networking company over events surrounding its controversial initial public offering. Facebook Inc (NASDAQ:FB) stock performance was 0.28% in last session and finished the day at $75.19. Traded volume was 385.00million shares in the last session and the average volume of the stock remained 49.28million shares. Facebook Inc (NASDAQ:FB) insider ownership … Continue reading Nasdaq active movers: Facebook Inc (NASDAQ:FB), Sirius XM Holdings (NASDAQ:SIRI), QUALCOMM (NASDAQ:QCOM), Glu Mobile Inc. (NASDAQ:GLUU), Gilead Sciences, Inc. (NASDAQ:GILD)

John Meady
Finance

Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

MannKind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, poised to launch its FDA approved drug, Afrezza, as treatment indications for both Type 1 and Type 2 diabetes. Despite near unanimous backing from experts at the Advisory Committee (ADCOM) and the medical community, Mr. Market is still pessimistic on the company.  MannKind Corporation (NASDAQ:MNKD) stock performance was -2.50% in last session and finished the … Continue reading Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

Jason Knox
Finance

Investors Alert – Gilead Sciences (NASDAQ:GILD) , Galena Biopharma (NASDAQ:GALE) , RPI , UnitedHealth (NYSE:UNH) , China Automotive (NASDAQ:CAAS)

Gilead Sciences’ controversial $1,000-a-day Sovaldi pill is priced in line with previous treatments for Hepatitis C, but the nation’s health-care system likely won’t be able to handle that kind of sticker shock, and competition probably will bring down that price tag in coming months and years. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 4.84% in last session and finished the day at $89.19. Traded volume … Continue reading Investors Alert – Gilead Sciences (NASDAQ:GILD) , Galena Biopharma (NASDAQ:GALE) , RPI , UnitedHealth (NYSE:UNH) , China Automotive (NASDAQ:CAAS)

Jason Knox